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design; 3 level dose were tested: 50-60-75 mg/mq/die for 5 
days/week. Primary endpoint was to define the Maximum Tollerate 
Dose (MTD); acute toxicity (RTOG/EORTC) considered dose-limiting 
was: any grade >4 hematological toxicity or any grade 3 or 4 hepatic 
toxicity. Secondary endpoint were clinical outcomes in terms of 
radiation therapy response rate, disease free survival (DFS) and 
overall survival (OS). 
Results: From April 2007 to June 2011, 9 patients were enrolled: 5 
male and 4 female. Median age was 67 yrs (range 50-76). IELSG at 
diagnosis was 0 in 2 patients, 1 and 2 in three patients respectively, 4 
in only one patients. Three of nine patients received only one cycle of 
HD-MTX because of hepatic, renal and haematological toxicity 
respectively. Seven patients had single lesion while 2 patients had 
multiple lesions; total lesions were 12. After HD-MTX 4/12 lesions had 
unconfirmed complete response (CRu), 5/12 had partial response (PR) 
and 3 showed progressive disease (PD). None dose-limiting toxicities 
was recorded. Acute toxicity was very low: one patients developed 
grade 2 white blood cells toxicity, and two patients developed grade 1 
hepatic toxicity. At a median follow up of 43 months, (range 18-69) 
6/9 patients (66.6%) are alive without disease, two older patients died 
because of disease and one patients died because of other causes. 
Median OS is 50 months with at 3 yrs OS of 78%. Median DFS has not 
yet reached, while at 3-yrs DFS is 74%. 
Conclusions: The MTDs for the combination of RT and Temozolomide 
after HD-MTX was not reached; standard dose of Temozolomide (75 
mg/mq/die) can be safely used associated to radiotherapy. Further 
studies are warranted to define clinical outcomes. 
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Purpose/Objective: Complex skull base tumors, such as large 
meningiomas and schwannomas, pose unique management challenges 
because of their irregular shapes, proximity and involvement of 
critical normal structures, and variable tumor volumes. Surgical 
decompression is often desired to relieve mass effect on brainstem 
and other critical structures, including cranial nerves, but gross total 
removal is often not possible without significant neurologic morbidity. 
We present preliminary outcomes of a feasibility study of planned 
subtotal resection with intelligent, computer-assisted, intra-operative 
guidance (Adaptive Hybrid Surgery) for management of these 
patients. 
Materials and Methods: To date, five patients with complex skull base 
tumors (2 large vestibular schwannomas, and 3 petroclival 
meningiomas) underwent computer-assisted, planned subtotal 
resection (STR), three of which were staged resections, followed by 
adjuvant stereotactic radiotherapy (SRT) or radiosurgery (SRS). Pre-
operative RT plans (designed to maximize tumor coverage) were 
uploaded into cranial navigation and stereotactic planning system. 
Resection approach and goals were planned pre-operatively, and 
extent of resection (EOR) was defined intraoperatively, iteratively, 
and in real-time by the operating neurosurgeon. Expected post-
operative SRT or SRS toxicity was estimated in near real-time using a 
set of pre-defined parameters during surgery to inform and guide 
resection extent with the aim of sculpting the tumor to create an 
ideal radiosurgical target. When estimates of post-op RT toxicity met 
predefined criteria, resection was halted and patients went on to 
received post-operative RT (within 1 month of surgery). 
Results: Pathologic review of surgical specimens was consistent with 
benign tumor histology in all five cases. Pre- and post-operative RT 
planning was performed successfully in all cases; without surgical 
resection, all 5 lesions would require conventionally-fractionated SRT 
in the adjuvant setting; however, 3 cases were eligible for (and 
successfully converted to) a 5-day SRS treatment following computer-
guided tumor debulking and were treated in that manner. With 
median follow-up period of 20.0 months (range, 6-31 months), no 
tumor recurrences were observed and all patients experienced stable 
or improved neurologic function (one stable, 4 improved) compared to 
pre-operative baseline. 
Conclusions: We have demonstrated the feasibility of adaptive, multi-
modality management of complex skull base tumors with intra-
operative software guidance. The approach of guided and selective 
'tumor sculpting' in the setting of subtotal resection with planned 
adjuvant SRT is expected to result in tumor control rates that are in 
line with historical data, and has the potential to convert cases of 
adjuvant conventionally-fractionated SRT to SRS cases, thereby 
decreasing overall treatment time while minimizing both surgical and 
radiotherapy morbidity.  
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Purpose/Objective: To assess safety and efficacy of hypofractionated 
therapy followed by low dose radiation therapy (LDRT) combined with 
Temozolomide in adults with newly diagnosed Glioblastoma 
Multiforme (GBM).  
Materials and Methods: Patients (KPS > 70, age >18 years) who 
underwent to biopsy or who presented gross residual tumor after 
surgery were enrolled. Hypofractionated dose (30 Gy in ten fractions) 
combined with Temozolomide (75 mg/m2 daily from start to end RT) 
was delivered before LDRT. Beginning with second adjuvant TMZ (200 
mg/m2 daily for 5 days every 28 days) patients received two daily 
doses of 0.40 Gy, at least 4 hours apart, for 5 days; 2-4 cycles were 
planned. Conformal irradiation included the tumor bulk with surgical 
cavity, plus a 30-mm margin. The primary endpoints as safety, toxicity 
and tolerability were evaluated according to the Common Terminology 
Criteria for Adverse Events version 4.0. The secondary endpoints were 
the response, according to the RECIST Guidelines, the overall survival 
(OS) and the progression-free survival (PFS) calculated by the Kaplan-
Mayer method. 
Results: From June 2008 to January 2012, 20 patients (M/F: 1), with a 
median age was 64.5 years (range 43-75), were enrolled. All patients 
received the prescribed dose of 30 Gy. The median dose of LD-FRT 
was 12 Gy (range 3-24 Gy), equal to two cycles; 11/20 (55%) 
underwent to <2 cycles and 9/20 (45%) to > 2 cycles. All toxicities 
were reversible and only 5 patients (25%) presented hematologic 
toxicity, grade 1-2 of leukopenia and thrombocytopenia in 4/5 
patients. Regarding the whole sample median OS and PFS from initial 
diagnosis were 18 and 11 months, respectively. According to the 
number of cycles, a median OS of 8 months and PFS of 5 months was 
observed in patients underwent to <2 cycles while a median OS of 27 
months and PFS of 12 months when four cycles were administered. 
Conclusions: Hypofractionated regimen followed by LDRT combined 
with TMZ is safe, well tolerated and may prolong the survival of 
patients with GBM. Further investigation is warranted; a new trial 
with different hypofractionated and LDRT dose is ongoing.  
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Purpose/Objective: Prospective evaluation of outcomes, toxicity, and 
quality-of-life of patients with oropharyngeal cancer (OPC) treated by 
IMRT and stereotactic body radiotherapy boost. 
Materials and Methods: Between 2004 and 2011, 132 consecutive 
patients with T1-4N0-3 OPC were treated with (chemo)radiotherapy 
with 46-Gy of IMRT to the primary tumor and the neck followed by a 
boost to the primary tumor by means of the Cyberknife (stereotactic 
body radiotherapy). Patients with node-positive disease received neck 
dissection 2-3 weeks after finishing radiotherapy. Endpoints were 
locoregional control (LRC), disease-free survival (DFS), and overall 
survival (OS), toxicity using Common Terminology Criteria for Adverse 
Events v3.0 (CTCAE) and QoL-assessment using the EORTC QLQ-C30 
and QLQ-H&N35. 
Results: After a median follow-up of 30 months, the 3-year actuarial 
incidence of LRC, DFS, and OS were 93, 85%, and 76%, respectively. 
Nine locoregional failures were reported. No single failure was 
observed in patients with T1 or T2 and in patients with HPV-related 
disease. At the end of treatment, 26% of patients had tube feeding. 
On the mutltivariate analysis tumor stage, chemotherapy and 
unilateral neck irradiation were significantly correlated with tube 
feeding. For the whole group, the overall incidence of grade ≥2 late 
toxicity was 23%. The incidence of grade ≥2 late dysphagia and 
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xerostomia were 13% and 17%, respectively. Tumor stage, unilateral 
neck irradiation, and tumor subsite (p<0.001) correlated with late 
toxicity. For the whole group, clinically relevant deterioration was 
seen on the QLQ-H&N35 dry mouth scale (-21, compared to baseline), 
while the scores on the QLQ-H&N35 swallowing were returned to 
baseline level. Unilateral neck irradiation was the most significant 
predictor for better scores on the QLQ-H&N35 dry mouth scale.  
Conclusions: Excellent outcomes were achieved in patients treated 
with 46 Gy of IMRT followed by a stereotactic body radiotherapy boost 
by means of the Cyberknife. No single failure was reported in patients 
with low tumor stage and HPV-related disease. This highly-conformal 
boost technique significantly reduced toxicity and improved QoL-
scores without jeopardizing outcomes. However, patient-reported 
xerostomia remains a major problem. Because unilateral neck 
irradiation was the most significant predictor for better scores on 
QLQ-H&N35 dry mouth scale, expanding the indications for this 
treatment approach needs to be thoroughly investigated in 
prospective trials. Given the increasing incidence of HPV-related OPC 
in the last decades especially among young patients, further reduction 
of the incidence of these troublesome complications is, therefore, 
mandatory.  
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Purpose/Objective: In radiation oncology 18F-FDG PET imaging has 
increasingly been investigated for prediction and monitoring of 
treatment response. The integrated SUV (iSUV) has been reported to 
be associated with treatment outcome in HNSCC. We investigated the 
predictive power of iSUV and its comparison with commonly used 18F-
FDG PET derived metrics (i. e. SUVmax, SUVmean), tumor volume and the 
TNM staging system in squamous cell carcinomas of the head and 
neck.  
Materials and Methods: Eightyone (cT1 – cT4) HNSCC patients treated 
with radiotherapy or chemo-radiation were included retrospectively. 
39 patients had a tumor of the larynx and 41 patients had an 
oropharynx tumor. All patients underwent an 18F-FDG-PET-CT scan for 
radiation treatment planning and the primary tumor was delineated 
by an experienced radiation oncologist on the fused images PET and 
CT images (Figure 1a). Basic SUV uptake metrics were extracted from 
the primary GTV, including SUVmax, SUVmean, and iSUV defined as the 
product of tumor volume and SUVmean. The non-parametric Mann-
Whitney U test and the log rank test were used to determine 
statistical significant differences on overall survival groups. For TNM 
the Chi-square test was used. Univariate Cox proportional-hazards 
models were used compared the risk of death among patients. A 5-
fold cross validated c-index was determined to evaluate the model’s 
performance. 
Results: The median survival time was 37 months (95% CI, 33-41 
months) and the median follow up was 30 months (range: 0.7-41), 
with an event rate of 28 %. iSUV was significantly associated with 
overall survival (p = 0.001) and showed a 5-fold cross validation c-
index of 0.78. The comparison with TNM and other evaluated 
parameters is summarized in Table 1. For comparison, Kaplan Meier 
curves are shown in Figure 1b.  
 
Table 1. Univariate association with overall survival 
 iSUV SUVmax SUVmean Tumor 
volume 
TNM 
Non-parametric test 
(p-value) 
0.001 0.011 0.080 0.000 0.135 
Log Rank test (p-
value) 
0.010 0.117 0.302 0.009 0.139 
C-index 0.78 0.70 0.62 0.77 0.68 
 
Conclusions: In line with previous findings, the integrated SUV is an 
important predictor of overall survival in HNSCC. The TNM staging 
system showed a limited value as prognostic factor. iSUV had a better 
prognostic performance than the most commonly used 18F-FDG-PET-CT 
derived metrics, however it was not a better predictor than tumor 
volume. Analysis of an extended cohort and a tumor anatomical sub-
location analysis will follow.  
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Purpose/Objective: Randomized controlled trials are the cornerstone 
of evidence-based medicine. Therefore, quality assurance (QA) of 
these trials is of vital importance. QA has various aspects, such as 
monitoring, image QA and treatment planning QA. We describe the 
latter aspect for a randomized international multicenter phase II trial 
for head and neck cancer: 'Adaptive and innovative Radiation 
Treatment FOR improving Cancer treatment outcomE (ARTFORCE)' 
(registered with ClinicalTrials.gov number NCT01504815).  
In ARTFORCE patients are randomized between chemoradiotherapy 
with concurrent cisplatin or Cetuximab and between standard 
radiotherapy (RT) and redistributed adaptive RT with a maximum dose 
up to 84Gy, resulting in four treatment arms (Figure 1). Because the 
planning of redistributed RT dose requires a novel approach, we will 
discuss its QA. 
 Materials and Methods: First, consensus was reached by the 
participating centers on delineation and treatment planning 
guidelines. A contouring atlas was made and dose objectives and 
constraints were set, which were subsequently used in the dummy 
run. For the dummy run, an anonymized CT scan and delineations 
were provided to all participating centers for treatment planning of 
